Search Results - technology+classifications+%3e+therapeutic+modalities+%3e+immunotherapies

44 Results

Sort By:

Targeted T-VEC immunotherapy for cutaneous neurofibromas

Value Proposition· Tumor-selective oncolysis: T‑VEC is an engineered oncolytic HSV‑1 that preferentially replicates in and lyses tumor cells, providing direct cytolytic reduction of cutaneous neurofibromas in preclinical models· Local, anti-tumor immune activation: preclinical evidence that tumor cell lysis and local GM-CSF expression promotes...

Published: 4/24/2026 | Inventor(s): Renyuan Bai, Verena Staedtke, Jaishri Blakeley, Carlos Romo

Keywords(s):

Category(s): Clinical and Disease Specializations > Genetic Diseases, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Repurposed Drugs, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Immunotherapies, Clinical and Disease Specializations > Immuno-Oncology

Single-construct Co-expression of Immune Activation Signals for Immunotherapy

Value Proposition:· Dual specific targeting for improved full T-cell and amplification.· Interchangeable protein components can be customized for cancer, infectious disease, and autoimmune disorder therapies.· Deliverable by nanoparticles into cells in vivo, in vitro, and ex vivo for immune activation.Unmet Need:Immunotherapy is a rapidly...

Published: 4/24/2026 | Inventor(s): Jordan Green, Joanna Yang, Stephany Tzeng, Jamie Spangler

Keywords(s):

Category(s): Technology Classifications > Therapeutic Modalities > Gene Therapies, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities > Proteins, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Research Tools > Vectors & Plasmids, Technology Classifications > Research Tools > Proteins, Ligands & Receptors, Technology Classifications > Research Tools > Nucleic Acids

Targeting of Myeloid-Derived Suppressor Cells (MDSCs) for Cancer Treatment

Value Proposition· Addresses key resistance mechanism: targets MDSCs, a central driver of resistance to immune checkpoint inhibitors in metastatic and poorly immunogenic cancers· Synergistic combination strategy: Combines epigenetic modulators (HDAC and DNA methyltransferase inhibitors) with anti-PD-1 and anti-CTLA-4 antibodies to restore...

Published: 4/23/2026 | Inventor(s): KiBem Kim, Bert Vogelstein, Kenneth Kinzler, Shibin Zhou

Keywords(s): Antagonists/Inhibitors, Antibodies, Biologics, Cancers, Combination, Disease Indication, Non-novel, Predicted Novelty, Repurposed, Small Molecules, Targeted Therapy/Immunotherapy, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities

Targeted chemo-immunotherapy delivery

Value PropositionEnhanced effect of immunotherapyTreatment for recurrent or metastatic diseaseImproved glioma treatment Unmet NeedImmunotherapy represents a new paradigm in cancer treatment. Molecules that effectively reverse the immune suppressing nature of cancer have the potential to enhance the body’s ability to work systemically combat cancer (Pardoll,...

Published: 4/23/2026 | Inventor(s): Dimitrios Mathios, Betty Tyler, Drew Pardoll, Henry Brem, Michael Lim

Keywords(s): Antagonists/Inhibitors, Cancers, Chemotherapy/Immunotherapy, Combination, Disease Indication, Non-novel, Predicted Novelty, Repurposed, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Immunology, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities

VR-Expressing Cells against Multiple Cytokines and Uses Thereof

Unmet Need· Recent technological breakthroughs have highlighted the therapeutic potential of immunotherapy (e.g., CAR-T cells) and have focused attention and efforts on developing safe and effective immunotherapy modalities.· Despite advances in the field, there remain several challenges to both efficacy and safety of CAR-T and other immunotherapies.· CAR-T...

Published: 4/24/2026 | Inventor(s): Adrian Johnston, Denis Wirtz

Keywords(s):

Category(s): Technology Classifications > Therapeutic Modalities > Immunotherapies, Clinical and Disease Specializations > Immuno-Oncology

Immune-modulating nanoparticles as a versatile genetic vaccination platform

Value PropositionVersatile immunotherapy platform with the ability to specifically target antigen presenting cells (APCs) ) following systemic delivery and without requiring targeting ligands to improve treatment efficacy. Flexibility to modulate the immune system through activation or inducing tolerance.Useful as a preventative strategy or therapeutic...

Published: 4/24/2026 | Inventor(s): Jordan Green, Elana Ben-Akiva, Johan Karlsson, Stephany Tzeng, Kelly Rhodes, Sarah Neshat

Keywords(s):

Category(s): Clinical and Disease Specializations > Autoimmunity, Clinical and Disease Specializations > Immunology, Technology Classifications > Medical Devices > Therapeutic Devices, Technology Classifications > Therapeutic Modalities > Dendrimers & Polymers, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities > Vaccines

Engineered Cytokine-antibody Fusion for Targeted Expansion of Immune Effector Cells

Unmet NeedGlobal revenue from the cytokine therapeutics market was valued at approximately $16.5 billion in 2018, and cytokine immunotherapy is a promising field of anti-cancer treatments for a broad range of cancer types. In particular, interleukin-2 (IL-2) therapy is shown to stimulate anti-cancer immunity. However, IL-2 activates contradictory immune...

Published: 4/24/2026 | Inventor(s): Jamie Spangler, Jakub Tomala, Michael Leff, Seth Ludwig, Elissa Leonard, Marek Kovar, Jirina Kovarova

Keywords(s): Biologics, Cancers, Disease Indication, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Antibodies, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities > Biologics

Antibodies Against CCAR1 Confer Protection Against Cancer

Brief DescriptionStanford and JHU researchers identify an autoantibody response in dermatomyositis patients that is protective of cancer, which may have applications in cancer screening and treatment.Technology Summary Researchers at Stanford University and Johns Hopkins University have identified an antibody that is negatively associated with cancer...

Published: 4/24/2026 | Inventor(s): Antony Rosen, Livia Casciola-Rosen, David Fiorentino

Keywords(s):

Engineered Tolerogenic Artificial Antigen-presenting Cells for Specific Expansion of Regulatory T Cells

Unmet NeedGlobal incidence of autoimmune disease is on the rise, and currently one in twelve Americans (including one in 9 women) suffer from autoimmune disease. Particularly, Type 1 Diabetes (T1D) represents a highly prevalent autoimmune disease, affecting over 20 million people. These diseases occur when the body’s immune system incorrectly attacks...

Published: 4/24/2026 | Inventor(s): Jordan Green, Jamie Spangler, Stephany Tzeng, Kelly Rhodes, Giorgio Raimondi, Marcos Iglesias Lozano, Jakub Tomala, Derek VanDyke, Randall Meyer

Keywords(s): Autoimmune Diseases, Biologics, Discovery/Research Tools, Disease Indication, Drug Delivery Vehicle, Inflammatory Disorders, Polymers, Recombinant Proteins, Research Reagent, Therapeutic Matter, Therapeutic Substance, Therapeutics, Transplants

Category(s): Clinical and Disease Specializations > Autoimmunity, Clinical and Disease Specializations > Transplantation, Clinical and Disease Specializations > Diabetes > Type 1 Diabetes, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Research Tools, Technology Classifications > Therapeutic Modalities > Cell Therapies

Targeting PTPN22 in Cancer Therapy

Unmet NeedTumor-infiltrating lymphocytes (TILs) such as B-cells, T-cells, and natural killers are gaining traction in anti-tumor immune responses. TILs involve the use of special immune cells called T-cells, otherwise known as lymphocytes, which protect the body from viral infections, fight cancer, and coordinate the activities of other cells during...

Published: 4/24/2026 | Inventor(s): Elizabeth Jaffee, Won Jin Ho, Soren Charmsaz

Keywords(s): Cancers, Combination, Discovery/Research Tools, Disease Indication, In Vivo Research Tool, Knock Out Mouse Model, Mouse Model, Target, Targeted Therapy/Immunotherapy, Therapeutic Matter, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Research Tools > Animal Models

1 2 3 4 5